Skip to main content
. 2020 Mar 9;130(4):1879–1895. doi: 10.1172/JCI129012

Figure 1. Systemic Mir181ab1 ablation impairs Kras-driven lung cancer.

Figure 1

(A) Representative H&E-stained sections of K181+/+ and K181–/– lungs 20 weeks after adCre infection. Scale bars: 5 mm. (B) Average tumor area percentage in K181+/+ (n = 9) and K181–/– (n = 8) groups compared by t test. (C) Mean number of tumors per mouse in K181+/+ (n = 9) and K181–/– (n = 8) mice compared by t test. (D) Average tumor size in K181+/+ (n = 632) and K181–/– (n = 222) groups compared by Mann-Whitney U test. (E) Left: Average percentage of Ki67+ cells in tumors from K181+/+ (n = 9) and K181–/– (n = 8) mice compared by t test. Right: Immunohistochemistry for Ki67 expression in representative sections. Scale bars: 200 μm and 50 μm (insets). (F) Kaplan-Meier plot of K181+/+ (n = 23, median survival = 151.5 days) and K181–/– (n = 19, median survival = 217 days) mice (log-rank test).